A new immunotherapy drug, atezolizumab, has been approved for patients with metastatic urothelial carcinoma, a type of bladder cancer. The drug represents the first new treatment for this form of the disease in more than ...
Jun 1, 2016
0
115
A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug ...
Dec 28, 2022
0
44
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 ...
Jun 6, 2022
0
2
A global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with ...
Jul 6, 2023
1
45
Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic ...
Jan 30, 2021
0
2
Updated toxicity data from the ongoing SWOG/NRG 1806 clinical trial, which tests combining chemoradiation therapy with immunotherapy in patients with localized muscle-invasive bladder cancer, reveal no significant safety ...
Oct 25, 2022
0
9
(HealthDay)—For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in longer overall survival than chemotherapy, according to a study ...
Oct 1, 2020
0
1
Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.
Apr 12, 2018
0
7
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) ...
Nov 22, 2019
0
6
An interim analysis of overall survival data from the IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC > 1% stage II-IIIA population (OS HR, 0.71 [95% CI: 0.49, 1.03]), but not in ...
Aug 8, 2022
0
17
